Replicel Life Sciences Inc V.RP

Alternate Symbol(s): REPCF

Technology Scientific & Technical Instruments

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.

TSXV:RP - Post by User

Replicel Life Sciences Inc

Bullboard Posts

Comment by MetzGERon Aug 11, 2020 9:05am

77 Views

Post# 31391708

RE:RE:RE:Hairloss2020.com post

Dr Tsuji is working with organ technologies, Kyocera and RIKEN,
It is not about cell injections like RCH-01.
they take hair biopsies of the back from the head and are able to clone the hair follicles then transplant it back in the scalp.

it is a FULL cure for people who lost all their hair.

my point ever was that Replicel is a nice solution for young people who notice some signs of balding then getting RCH-01 injections for maintenance.

but full regrowth is only possible with Takashi Tsujis solution. This will be much more expensive ~300.000$ compared to RCH-01 (1000$)

Bullboard Posts

Advancing flagship Ishkõday Gold Project in Ontario